Merit Medical Systems Earnings Call Transcripts
Fiscal Year 2026
-
Shareholders approved all proposals, including director elections and compensation plans, and welcomed a new CEO and director. The company reported record financial results, continued innovation, and outlined ongoing strategic growth initiatives.
-
Revised summary: Leadership emphasized a shift to platform-based management, aligning reporting with operations and focusing on scaling through people, process, and innovation. Growth is driven by foundational and therapeutic platforms, with acquisitions expanding offerings. Margin expansion and diversified growth remain priorities, with ongoing strategic planning and prudent M&A.
-
Q1 2026 delivered strong revenue and profit growth, exceeding expectations, with record non-GAAP operating margin and robust free cash flow. Strategic acquisitions, notably View Point Medical, expanded the oncology platform and future growth prospects.
-
New leadership is driving a smooth transition with a continued focus on customer-centric innovation and disciplined M&A. Strong financial performance includes 11% revenue growth in 2025 and improved margins, with high-growth therapeutic products and strategic acquisitions fueling future expansion.
Fiscal Year 2025
-
Q4 and full year 2025 results exceeded guidance, with double-digit revenue growth, record gross margin, and strong free cash flow. 2026 guidance calls for continued revenue and margin expansion, despite tariff and divestiture headwinds, and ongoing investment in growth platforms.
-
Leadership transition brings renewed focus on growth through 2026, with strong confidence in meeting financial targets despite tariff impacts. Wrapsody's launch is progressing well, supporting broader portfolio momentum, while M&A strategy will become more targeted and intentional.
-
Q3 2025 saw 13% revenue growth, record gross margin, and strong free cash flow, with cardiovascular outpacing expectations and endoscopy integrating recent acquisitions. Updated 2025 guidance reflects higher revenue and EPS, while tariff and regulatory risks persist.
-
Q2 2025 saw revenue and margin growth above expectations, driven by strong U.S. demand, successful acquisitions, and robust execution. Guidance for 2025 was raised, though tariff and reimbursement uncertainties persist, especially for WRAPSODY CIE.
-
Q1 2025 saw revenue and margin growth above expectations, driven by strong U.S. demand and successful integration of acquisitions. 2025 guidance was revised lower for EPS and margin due to $26.3 million in tariff-related costs, with mitigation efforts underway and robust free cash flow still expected.
-
WRAPSODY’s U.S. launch is progressing with strong clinical data, positive physician feedback, and reimbursement decisions expected in June. International growth is focused outside China, and recent M&A is enhancing product portfolios and salesforce efficiency.
-
FDA PMA approval for Rhapsody CIE enables U.S. launch, targeting a $7–$9M revenue range in 2025 with a premium ASP of $5,800. Strong clinical data and a robust commercial strategy support adoption, with reimbursement decisions expected mid-year.
-
Revenue reached $1.4 billion with strong Q4 results and robust OEM growth. WRAPSODY received FDA approval and is expected to drive future growth, while recent acquisitions and disciplined capital allocation support strategic expansion. Further guidance on 2025 and WRAPSODY ramp will be provided at upcoming investor events.
Fiscal Year 2024
-
Q4 and full year 2024 delivered record revenue, margins, and free cash flow, with strong growth in both cardiovascular and endoscopy segments. 2025 guidance calls for 8%-10% revenue growth, continued margin expansion, and at least $150 million in free cash flow, with tariff risks and integration of recent acquisitions being closely monitored.
-
Continued Growth Initiatives and targeted sales strategies are driving market share gains across key geographies, despite headwinds in China. WRAPSODY's anticipated FDA approval and launch are set to boost brand equity and support related product lines, while financial guidance remains focused on 5%-7% growth and balanced performance across revenue, margin, and cash flow.
-
Management succession is underway with a new president and active CEO search. WRAPSODY's FDA approval is expected in Q1 2025, with reimbursement and commercial plans progressing. Organic growth remains strong, margins are improving, and long-term targets for revenue, margin, and cash flow are on track.
-
Q3 revenue and profitability exceeded expectations, driven by strong organic and acquired growth, with robust free cash flow and margin expansion. The Cook Medical acquisition and Wrapsody program are set to further boost growth, while guidance for 2024 was raised across key metrics.
-
WRAPSODY’s strong clinical data positions it as a potential new standard in dialysis care, with PMA approval expected in Q1 2025. Commercial infrastructure and reimbursement strategies are being finalized, while broad-based growth continues across business segments. Financial targets remain on track, with margin expansion and free cash flow generation prioritized.
-
Leadership is focused on succession planning, margin improvement, and commercial excellence. Wrapsody's pivotal trial data is imminent, with strong market potential and expected margin accretion. Financial performance remains robust, with growth in China, OEM recovery, and strong free cash flow.
-
Leadership is focused on executing long-term plans, talent development, and margin improvement. Rhapsody’s pivotal data is imminent, with commercial and reimbursement strategies in progress. Financial performance is strong, with robust cash flow, ongoing operational efficiencies, and strategic M&A integration supporting future growth.
-
Strong organic growth, margin expansion, and robust free cash flow highlight recent performance, with new guidance raised for FY. Strategic M&A, including EGS, is expanding the endoscopy segment, while the WRAPSODY PMA product and a disciplined pipeline signal continued innovation.
-
Q2 revenue and profitability exceeded expectations, with strong growth in both cardiovascular and endoscopy segments. Updated 2024 guidance reflects higher revenue, EPS, and free cash flow, supported by the accretive EndoGastric Solutions acquisition and robust US and international demand.